Skip to main content

Tango Therapeutics, Inc 8-K, filed Oct 23, 2026

Tango Therapeutics, Inc. (TNGX)

8-K 2026-10-23 For: 2026-10-23
View Original
Added on October 23, 2026

About this 8-K

Tango Therapeutics, Inc filed this 8-K on October 23, 2026.

Tango Therapeutics reported an 82% objective response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with second line or third line MTAP-deleted/RAS-mutant pancreatic cancer. It plans to start a randomized registrational trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. It also intends to reduce its workforce by approximately 14% as part of a strategic reprioritization. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits